Gp130 receptor ligands as potential therapeutic targets for obesity

Journal of Clinical Investigation

Volumn 117, Issue 4, 2007, Pages 841-849

  Febbraio, Mark A ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; GLYCOPROTEIN GP 130; GLYCOPROTEIN GP 130 RECEPTOR LIGAND; INTERLEUKIN 6; LEPTIN; UNCLASSIFIED DRUG;

DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID OXIDATION; LIPID STORAGE; NAUSEA; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; WEIGHT CONTROL;

CILIARY NEUROTROPHIC FACTOR; CYTOKINE RECEPTOR GP130; FEEDING BEHAVIOR; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; LEPTIN; OBESITY; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 34147159710     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30453     Document Type: Review

References (113)

1. Flegal, K.M., Carroll, M.D., Ogden, C.L., and Johnson, C.L. 2002. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 288:1723-1727.
2. Mascie-Taylor, C.G., and Karim, E. 2003. The burden of chronic disease. Science. 302:1921-1922.
3. Garcia, S.B., et al. 2006. The anti-obesity agent Orlistat is associated to increase in colonic pre-neoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 240:221-224.
4. Padwal, R.S., and Majumdar, S.R. 2007. Drug treatment for obesity: orlistat, sibutramine, and rimonbant. Lancet. 369:71-77.
5. Giorgino, F., Laviola, L., and Leonardini, A. 2005. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res. Clin. Pract. 68(Suppl. 1):S22-S29.
6. Zhang, Y., et al. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:425-432.
7. Halaas, J.L., et al. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 269:543-546.
8. Kennedy, G.C. 1953. The role of depot fat in the hypothalamic control of food intake in the rat. Proc. R. Soc. Lond. B Biol. Sci. 140:578-592.
9. Coleman, D.L. 1973. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia. 9:294-298.
10. Elmquist, J.K., et al. 1998. Leptin activates distinct projections from the dorsomedial and ventromedial hypothalamic nuclei. Proc. Natl. Acad. Sci. U. S. A. 95:741-746.
11. Friedman, J.M., and Halaas, J.L. 1998. Leptin and the regulation of body weight in mammals. Nature. 395:763-770.
12. Schwartz, M.W., Erickson, J.C., Baskin, D.G., and Palmiter, R.D. 1998. Effect of fasting and leptin deficiency on hypothalamic neuropeptide Y gene transcription in vivo revealed by expression of a lacZ reporter gene. Endocrinology. 139:2629-2635.
13. Bjørbæk, C., and Kahn, B.B. 2004. Leptin signaling in the central nervous system and the periphery. Recent Prog. Horm. Res. 59:305-331.
14. Kahn, B.B., Alquier, T., Carling, D., and Hardie, D.G. 2005. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1:15-26.
15. Minokoshi, Y., et al. 2004. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 428:569-574.
16. Minokoshi, Y., et al. 2002. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 415:339-343.
17. Steinberg, G.R., Rush, J.W., and Dyck, D.J. 2003. AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. Am. J. Physiol. Endocrinol. Metab. 284:E648-E654.
18. Watt, M.J., et al. 2006. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat. Med. 12:541-548.
19. Tartaglia, L.A., et al. 1995. Identification and expression cloning of a leptin receptor, OB-R. Cell. 83:1263-1271.
20. Baumann, H., et al. 1996. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc. Natl. Acad. Sci. U. S. A. 93:8374-8378.
21. Flier, J.S. 2004. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 116:337-350.
22. Van Heek, M., et al. 1997. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J. Clin. Invest. 99:385-390.
23. Schwartz, M.W., et al. 1996. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat. Med. 2:589-593.
24. Naka, T., et al. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature. 387:924-929.
25. Yoshimura, A., et al. 1995. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14:2816-2826.
26. Starr, R., et al. 1997. A family of cytokine-inducible inhibitors of signalling. Nature. 387:917-921.
27. Howard, J.K., et al. 2004. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat. Med. 10:734-738.
28. Mori, H., et al. 2004. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat. Med. 10:739-743.
29. Yasukawa, H., Sasaki, A., and Yoshimura, A. 2000. Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18:143-164.
30. Bjørbæk, C., et al. 2000. Divergent roles of SHP-2 in ERK activation by leptin receptors. J. Biol. Chem. 276:4747-4755.
31. Eyckerman, S., et al. 2000. Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor. FEBS Lett. 486:33-37.
32. Ueki, K., Kondo, T., Tseng, Y.H., and Kahn, C.R. 2004. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. U. S. A. 101:10422-10427.
33. Steinberg, G.R., Parolin, M.L., Heigenhauser, G.J., and Dyck, D.J. 2002. Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance. Am. J. Physiol. Endocrinol. Metab. 283:E187-E192.
34. Considine, R.V., et al. 1996. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334:292-295.
35. Frederich, R.C., et al. 1995. Leptin and the regulation of body weight in mammals. Nat. Med. 1:1311-1314.
36. Farooqi, I.S., et al. 2002. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/ metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110:1093-1103. doi:10.1172/JCI200215693.
37. Rosenbaum, M., et al. 2005. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J. Clin. Invest. 115:3579-3586. doi:10.1172/JCI25977.
38. Weissenbach, J., et al. 1980. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc. Natl. Acad. Sci. U. S. A. 77:7152-7156.
39. Hirano, T., et al. 1986. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 324:73-76.
40. Yasukawa, K., et al. 1987. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J. 6:2939-2945.
41. Gadient, R.A., and Patterson, P.H. 1999. Leukemia inhibitory factor, interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells. 17:127-137.
42. Taga, T., et al. 1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 58:573-581.
43. Boulay, J.L., et al. 2003. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity. 19:159-163.
44. Zvonic, S., et al. 2005. Cross-talk among gp130 cytokines in adipocytes. J. Biol. Chem. 280:33856-33863.
45. Ernst, M., and Jenkins, B.J. 2004. Acquiring signaling specificity from the receptor gp130. Trends Genet. 20:23-32.
46. Cohen, B., Novick, D., and Rubinstein, M. 1996. Modulation of insulin activities by leptin. Science. 274:1185-1188.
47. Boulton, T.G., Stahl, N., and Yancopoulos, G.D. 1994. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. J. Biol. Chem. 269:11648-11655.
48. Cota, D., et al. 2006. Hypothalamic mTOR signaling regulates food intake. Science. 312:927-930.
49. Yokogami, K., Wakisaka, S., Avruch, J., and Reeves, S.A. 2000. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol. 10:47-50.
50. Janoschek, R., et al. 2006. gp130 signaling in proopiomelanocortin neurons mediates the acute anorectic response to centrally applied ciliary neurotrophic factor. Proc. Natl. Acad. Sci. U. S. A. 103:10707- 10712.
51. Schuster, B., et al. 2003. Signalling of human CNTF revisited: the interleukin-6 (IL-6) receptor can serve as an α-receptor for ciliary neurotrophic factor (CNTF). J. Biol. Chem. 278:9528-9535.
52. Wellen, K.E., and Hotamisligil, G.S. 2005. Inflammation, stress, and diabetes. J. Clin. Invest. 115:1111-1119. doi:10.1172/ JCI200525102.
53. Weisberg, S.P., et al. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112:1796-1808. doi:10.1172/JCI200319246.
54. Vozarova, B., et al. 2001. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res. 9:414-417.
55. Bastard, J.P., et al. 2000. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 85:3338-3342.
56. Lazar, M. 2005. How obesity causes diabetes: not a tall tale. Science. 307:373-375.
57. Rotter, V., Nagaev, I., and Smith, U. 2003. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and TNFalpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem 278:45777-45785.
58. Lagathu, C., et al. 2003. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem. Biophys. Res. Commun. 311:372-379.
59. Senn, J.J., Klover, P.J., Nowak, I.A., and Mooney, R.A. 2002. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 51:3391-3399.
60. Senn, J.J., et al. 2003. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 278:13740-13746.
61. Klover, P.J., Zimmers, T.A., Koniaris, L.G., and Mooney, R.A. 2003. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 52:2784-2789.
62. Klover, P.J., Clementi, A.H., and Mooney, R.A. 2005. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology. 146:3417-3427.
63. Kim, H.J., et al. 2004. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 53:1060-1067.
64. Kristiansen, O.P., and Mandrup-Poulsen, T. 2005. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 54(Suppl. 2):S114-S124.
65. Carey, A.L., and Febbraio, M.A. 2004. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia. 47:1135-1142.
66. Flores, M.B., et al. 2006. Exercise improves insulin and leptin sensitivity in hypothalamus of wistar rats. Diabetes. 55:2554-2561.
67. Kelly, M., et al. 2004. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem. Biophys. Res. Commun. 320:449-454.
68. Al-Khalili, L., et al. 2006. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol. Endocrinol. 20:3364-3375.
69. Carey, A.L., et al. 2006. IL-6 increases insulin stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMPK. Diabetes. 55:2688-2697.
70. Petersen, E.W., et al. 2005. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am. J. Physiol. Endocrinol. Metab. 288:E155-E162.
71. Bruce, C.R., and Dyck, D.J. 2004. Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am. J. Physiol. Endocrinol. Metab. 287:E616-E621.
72. van Hall, G., et al. 2003. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J. Clin. Endocrinol. Metab. 88:3005-3010.
73. Weigert, C., et al. 2004. Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. J. Biol. Chem. 279:23942-23952.
74. Weigert, C., et al. 2005. Interleukin-6 (IL-6) acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser-473 of Akt. Am. J. Physiol. Endocrinol. Metab. 289:E251-E257.
75. Weigert, C., et al. 2006. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J. Biol. Chem. 281:7060-7067.
76. Adler, R., Landa, K.B., Manthorpe, M., and Varon S. 1979. Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science. 204:1434-1436.
77. Lin, F.-L.H., et al. 1989. Purification, cloning and expression of ciliary neurotrophic factor. Science. 246:1023-1025.
78. Stöckli, K.A., et al. 1989. Molecular cloning, expression, and regional distribution of rat ciliary neurotrophic factor. Nature. 342:920-923.
79. Sleeman, M.W., et al. 2000. The ciliary neurotrophic factor and its receptor, CNTFRa. Pharm. Acta Helvet. 74:265-272.
80. Davis, S., et al. 1993. Released form of CNTF receptor alpha component as a soluble mediator of CNTF responses. Science. 259:1736-1739.
81. Chen, X., et al. 2005. Dedifferentiation of adult human myoblasts induced by ciliary neurotrophic factor in vitro. Mol. Biol. Cell. 16:3140-3151.
82. Guilett, C., et al. 1999. Ciliary neurotrophic factor is a regulator of muscular strength in aging. J. Neurosci. 19:1257-1262.
83. ALS CNTF Treatment Study Group. 1996. A double blind placebo-controlled clinical trial of subcutaneous recombinant ciliary neurotrophic factor (rH-CNTF) in amyotrophic lateral sclerosis. Neurology. 46:1244-1249.
84. Gloaguen, I., et al. 1997. Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc. Natl. Acad. Sci. U. S. A. 94:6456-6461.
85. Lambert, P.D., et al. 2001. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc. Natl. Acad. Sci. U. S. A. 98:4652-4657.
86. Kalra, S.P. 2001. Circumventing leptin resistance for weight control. Proc. Natl. Acad. Sci. U. S. A. 98:4279-4281.
87. Kelly, J.F., et al. 2004. Ciliary neurotrophic factor and leptin induce distinct patterns of immediate early gene expression in the brain. Diabetes. 53:911-920.
88. Prima, V., et al. 2004. Differential modulation of energy balance by leptin, ciliary neurotrophic factor, and leukemia inhibitory factor gene delivery: microarray deoxyribonucleic acid-chip analysis of gene expression. Endocrinology. 145:2035-2045.
89. Kokoeva, M.V., Yin, H., and Flier, J.S. 2005. Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science. 310:679-683.
90. Cowley, M.A., et al. 2003. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 37:649-661.
91. Vogel, G. 2005. Does brain cell growth drive weight loss? Science. 310:602.
92. Andersson, U., et al. 2004. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279:12005-12008.
93. Steinberg, G.R., et al. 2006. Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. Endocrinology. 147:3906-3914.
94. Ott, V., et al. 2002. Direct effects of ciliary neurotrophic factor on brown adipocytes: evidence for a role in peripheral regulation of energy homeostasis. J. Endocrinol. 173:R1-R8.
95. Zvonic, S., et al. 2003. The regulation and activation of ciliary neurotrophic factor signaling proteins in adipocytes. J. Biol. Chem. 278:2228-2235.
96. Ahima, R.S. 2006. Overcoming insulin resistance with CNTF. Nat. Med. 12:511-512.
97. Krssak, M., et al. 1999. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 42:113-116.
98. Kim, J.K., et al. 2004. PKC-θ knockout mice are protected from fat-induced insulin resistance. J. Clin. Invest. 114:823-827. doi:10.1172/JCI200422230.
99. Cai, D., et al. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11:183-190.
100. Hirosumi, J., et al. 2003. A central role for JNK in obesity and insulin resistance. Nature. 420:333-336.
101. Watt, M.J., Hevener, A., Lancaster, G.I., and Febbraio, M.A. 2006. Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of JNK in peripheral tissues. Endocrinology. 147:2077-2085.
102. Sleeman, M.W., et al. 2003. Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice. Proc. Natl. Acad. Sci. U. S. A. 100:14297-14302.
103. Bluher, S., et al. 2004. Ciliary neurotrophic factorAx15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice. Diabetes. 53:2787-2796.
104. Irrcher, I., Kirwan, A.F., and Hood, D.A. 2006. AMP-activated protein kinase-regulated activation of the PGC-1α promoter in skeletal muscle cells [abstract]. FASEB J. 20:A389.
105. Petersen, K.F., et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 350:664-671.
106. Mootha, V., et al. 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34:267-273.
107. Takahashi, R., et al. 1994. A null mutation in the human CNTF gene is not causally related to neurological diseases. Nat. Genet. 7:79-84.
108. Roth, S.M., et al. 2001. CNTF genotype is associated with muscular strength and quality in humans across the adult age span. J. Appl. Physiol. 90:1205-1210.
109. Munzberg, H., et al. 1998. Screening for variability in the ciliary neurotrophic factor (CNTF) gene: no evidence for association with human obesity. Exp. Clin. Endocrinol. Diabetes. 106:108-112.
110. O'Dell, S.D., et al. 2002. Null mutation in human ciliary neurotrophic factor gene confers higher body mass index in males. Eur. J. Hum. Genet. 10:749-752.
111. Ettinger, M.P., et al. 2003. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA. 289:1826-1832.
112. Kallen, K.J., et al. 1999. Receptor recognition sites of cytokines are organized as exchangeable modules. Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6. J. Biol. Chem. 274:11859-11867.
113. Scott, D.L., and Kingsley, G.H. 2006. Tumor necrosis factor inhibits rheumatoid arthritis. N. Engl. J. Med. 355:704-712.